Amgen Stock - Weekly outlook with earnings date and pipeline in view

Amgen opens the new week without fresh company-specific headlines from major wires, so investors are looking ahead to the next quarterly earnings date and upcoming pipeline catalysts across obesity, oncology and inflammation.

Edited by ad hoc news Earnings & Calendar Desk. Verified prior to publication on 06/22/2026, 13:21 CET. Details in the imprint.

Amgen (US0311621009) begins the new week without a fresh market-moving company announcement from major wires or its own investor-relations page. With the news flow muted, attention shifts to the timing of the next earnings release and the status of key late-stage drug programs according to recent market data providers.

What recent data show

Amgen has not published a new earnings release or major clinical update on its investor-relations page since its most recent quarterly report and subsequent presentations, and no fresh headline has appeared on Reuters or Bloomberg over the past 24 hours.

According to recent quote data compiled by MarketBeat and other financial portals, Amgen shares last closed at $337.60 on Nasdaq on 06/18/2026, with extended-hours indications fractionally lower around $337.00 in light pre-market trading.

Weekly outlook and earnings calendar

With the calendar relatively quiet this Monday, many investors are already looking toward Amgen’s next quarterly earnings release, which market data providers currently place in late July 2026, although the company has not yet posted an official date on its website.

In the meantime, investor focus is likely to center on upcoming medical and investor conferences where Amgen may provide further color on its pipeline, including obesity candidate AMG 133 (MariTide), biosimilars, and oncology assets that could shift revenue trends over the medium term.

Pipeline and strategic priorities

Beyond the earnings date, the week’s narrative around Amgen stock is shaped by its pipeline breadth, where management has previously highlighted obesity, cardiovascular disease and oncology as key growth pillars in prepared remarks and slide decks accessible via its investor-relations site.

Against this backdrop, any new data readouts, regulatory submissions or label expansions in these areas over the coming months could become catalysts that matter more for the long-term valuation than short-term trading noise, even if this specific week starts without fresh headlines.

How the company makes money

Amgen generates most of its revenue from innovative biologic medicines such as the cholesterol drug Repatha, the osteoporosis medicine Prolia and various oncology and inflammation therapies, complemented by a growing portfolio of biosimilars marketed globally.

Where the stock trades today

Amgen shares (US0311621009) trade on Nasdaq under the ticker AMGN, with the most recently reported regular-session close at $337.60 on 06/18/2026, 16:00 ET.

Key facts on Amgen stock

• Company: Amgen Inc.
• ISIN: US0311621009
• WKN: 867900
• Ticker: AMGN
• Venue: Nasdaq
• Price (as of 06/18/2026, 16:00 ET): 337.60 USD
• Market cap: 181,000,000,000 USD (as of 06/18/2026)
• Sector / Industry: Health Care / Biotechnology
• Index membership: Standard & Poor's 500 index, Nasdaq-100
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.